vs
渤健（BIIB）与Roper Technologies（ROP）财务数据对比。点击上方公司名可切换其他公司
渤健的季度营收约是Roper Technologies的1.2倍（$2.5B vs $2.1B），Roper Technologies净利率更高（15.8% vs 12.9%，领先2.9%），Roper Technologies同比增速更快（11.3% vs 2.0%），渤健自由现金流更多（$594.3M vs $507.0M），过去两年Roper Technologies的营收复合增速更高（10.5% vs 0.3%）
渤健是总部位于美国马萨诸塞州剑桥市的跨国生物技术企业，专注于神经系统疾病治疗领域。公司核心产品包括用于多发性硬化症的特菲达、万立能等多款药物，以及治疗脊髓性肌萎缩症的诺西那生钠、治疗弗里德赖希共济失调的Skyclarys，致力于为神经疾病和罕见病患者提供创新疗法。
罗珀技术公司是一家专注于科技领域的控股企业，通过持有并运营多家不同细分赛道的科技公司，在科技产业投资与资产管理领域形成了成熟的业务体系，在全球相关市场具备较高的行业影响力。
BIIB vs ROP — 直观对比
营收规模更大
BIIB
是对方的1.2倍
$2.1B
营收增速更快
ROP
高出9.3%
2.0%
净利率更高
ROP
高出2.9%
12.9%
自由现金流更多
BIIB
多$87.3M
$507.0M
两年增速更快
ROP
近两年复合增速
0.3%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $2.5B | $2.1B |
| 净利润 | $319.5M | $331.0M |
| 毛利率 | — | 69.4% |
| 营业利润率 | — | 27.2% |
| 净利率 | 12.9% | 15.8% |
| 营收同比 | 2.0% | 11.3% |
| 净利润同比 | 32.8% | 842.6% |
| 每股收益（稀释后） | $2.15 | $4.87 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BIIBROP
| Q1 26 | $2.5B | $2.1B | ||
| Q4 25 | $2.3B | $2.1B | ||
| Q3 25 | $2.5B | $2.0B | ||
| Q2 25 | $2.6B | $1.9B | ||
| Q1 25 | $2.4B | $1.9B | ||
| Q4 24 | $2.5B | $1.9B | ||
| Q3 24 | $2.5B | $1.8B | ||
| Q2 24 | $2.5B | $1.7B |
净利润BIIBROP
| Q1 26 | $319.5M | $331.0M | ||
| Q4 25 | $-48.9M | $428.4M | ||
| Q3 25 | $466.5M | $398.5M | ||
| Q2 25 | $634.8M | $378.3M | ||
| Q1 25 | $240.5M | $331.1M | ||
| Q4 24 | $266.7M | $462.3M | ||
| Q3 24 | $388.5M | $367.9M | ||
| Q2 24 | $583.6M | $337.1M |
毛利率BIIBROP
| Q1 26 | — | 69.4% | ||
| Q4 25 | 78.3% | 69.5% | ||
| Q3 25 | 73.4% | 69.5% | ||
| Q2 25 | 77.1% | 69.2% | ||
| Q1 25 | 74.1% | 68.7% | ||
| Q4 24 | 76.2% | 68.3% | ||
| Q3 24 | 74.1% | 69.2% | ||
| Q2 24 | 77.8% | 69.5% |
营业利润率BIIBROP
| Q1 26 | — | 27.2% | ||
| Q4 25 | -2.5% | 28.6% | ||
| Q3 25 | 22.0% | 28.4% | ||
| Q2 25 | 28.1% | 28.2% | ||
| Q1 25 | 12.8% | 27.9% | ||
| Q4 24 | 11.9% | 28.0% | ||
| Q3 24 | 18.3% | 28.1% | ||
| Q2 24 | 28.3% | 28.8% |
净利率BIIBROP
| Q1 26 | 12.9% | 15.8% | ||
| Q4 25 | -2.1% | 20.8% | ||
| Q3 25 | 18.4% | 19.8% | ||
| Q2 25 | 24.0% | 19.5% | ||
| Q1 25 | 9.9% | 17.6% | ||
| Q4 24 | 10.9% | 24.6% | ||
| Q3 24 | 15.8% | 20.8% | ||
| Q2 24 | 23.7% | 19.6% |
每股收益（稀释后）BIIBROP
| Q1 26 | $2.15 | $4.87 | ||
| Q4 25 | $-0.35 | $3.97 | ||
| Q3 25 | $3.17 | $3.68 | ||
| Q2 25 | $4.33 | $3.49 | ||
| Q1 25 | $1.64 | $3.06 | ||
| Q4 24 | $1.82 | $4.29 | ||
| Q3 24 | $2.66 | $3.40 | ||
| Q2 24 | $4.00 | $3.12 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $3.4B | $382.9M |
| 总债务越低越好 | — | $9.7B |
| 股东权益账面价值 | $18.7B | $18.8B |
| 总资产 | $29.5B | $34.6B |
| 负债/权益比越低杠杆越低 | — | 0.52× |
8季度趋势，按日历期对齐
现金及短期投资BIIBROP
| Q1 26 | $3.4B | $382.9M | ||
| Q4 25 | — | $297.4M | ||
| Q3 25 | — | $320.0M | ||
| Q2 25 | — | $242.4M | ||
| Q1 25 | — | $372.8M | ||
| Q4 24 | — | $188.2M | ||
| Q3 24 | — | $269.6M | ||
| Q2 24 | — | $251.5M |
总债务BIIBROP
| Q1 26 | — | $9.7B | ||
| Q4 25 | $6.3B | $9.3B | ||
| Q3 25 | $6.3B | — | ||
| Q2 25 | $6.3B | — | ||
| Q1 25 | $4.5B | — | ||
| Q4 24 | $6.3B | $7.6B | ||
| Q3 24 | $4.5B | — | ||
| Q2 24 | $6.3B | — |
股东权益BIIBROP
| Q1 26 | $18.7B | $18.8B | ||
| Q4 25 | $18.3B | $19.9B | ||
| Q3 25 | $18.2B | $20.0B | ||
| Q2 25 | $17.6B | $19.6B | ||
| Q1 25 | $17.0B | $19.2B | ||
| Q4 24 | $16.7B | $18.9B | ||
| Q3 24 | $16.4B | $18.5B | ||
| Q2 24 | $15.9B | $18.1B |
总资产BIIBROP
| Q1 26 | $29.5B | $34.6B | ||
| Q4 25 | $29.4B | $34.6B | ||
| Q3 25 | $29.2B | $34.6B | ||
| Q2 25 | $28.3B | $33.2B | ||
| Q1 25 | $28.0B | $31.4B | ||
| Q4 24 | $28.0B | $31.3B | ||
| Q3 24 | $28.3B | $31.6B | ||
| Q2 24 | $26.8B | $29.8B |
负债/权益比BIIBROP
| Q1 26 | — | 0.52× | ||
| Q4 25 | 0.34× | 0.47× | ||
| Q3 25 | 0.35× | — | ||
| Q2 25 | 0.36× | — | ||
| Q1 25 | 0.27× | — | ||
| Q4 24 | 0.38× | 0.40× | ||
| Q3 24 | 0.28× | — | ||
| Q2 24 | 0.40× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | — |
| 自由现金流经营现金流 - 资本支出 | $594.3M | $507.0M |
| 自由现金流率自由现金流/营收 | 24.0% | 24.2% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $2.4B | — |
8季度趋势，按日历期对齐
经营现金流BIIBROP
| Q1 26 | — | — | ||
| Q4 25 | $511.9M | $738.0M | ||
| Q3 25 | $1.3B | $869.5M | ||
| Q2 25 | $160.9M | $404.1M | ||
| Q1 25 | $259.3M | $528.7M | ||
| Q4 24 | $760.9M | $722.2M | ||
| Q3 24 | $935.6M | $755.4M | ||
| Q2 24 | $625.8M | $384.1M |
自由现金流BIIBROP
| Q1 26 | $594.3M | $507.0M | ||
| Q4 25 | $468.0M | — | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $134.3M | — | ||
| Q1 25 | $222.2M | — | ||
| Q4 24 | $721.6M | — | ||
| Q3 24 | $900.6M | — | ||
| Q2 24 | $592.3M | — |
自由现金流率BIIBROP
| Q1 26 | 24.0% | 24.2% | ||
| Q4 25 | 20.5% | — | ||
| Q3 25 | 48.4% | — | ||
| Q2 25 | 5.1% | — | ||
| Q1 25 | 9.1% | — | ||
| Q4 24 | 29.4% | — | ||
| Q3 24 | 36.5% | — | ||
| Q2 24 | 24.0% | — |
资本支出强度BIIBROP
| Q1 26 | — | 0.5% | ||
| Q4 25 | 1.9% | — | ||
| Q3 25 | 1.8% | — | ||
| Q2 25 | 1.0% | — | ||
| Q1 25 | 1.5% | — | ||
| Q4 24 | 1.6% | — | ||
| Q3 24 | 1.4% | — | ||
| Q2 24 | 1.4% | — |
现金转化率BIIBROP
| Q1 26 | — | — | ||
| Q4 25 | — | 1.72× | ||
| Q3 25 | 2.73× | 2.18× | ||
| Q2 25 | 0.25× | 1.07× | ||
| Q1 25 | 1.08× | 1.60× | ||
| Q4 24 | 2.85× | 1.56× | ||
| Q3 24 | 2.41× | 2.05× | ||
| Q2 24 | 1.07× | 1.14× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BIIB
| Product revenue, net | $1.8B | 71% |
| Royalty revenue on sales of OCREVUS | $317.2M | 13% |
| Contract manufacturing, royalty and other revenue | $246.9M | 10% |
| Biogen's share of pre-tax profits in the U.S. for RITUXAN, GAZYVA and LUNSUMIO | $94.7M | 4% |
| Alzheimer's collaboration Revenue | $59.5M | 2% |
| Other revenue from anti-CD20 therapeutic programs | $7.2M | 0% |
ROP
暂无分部数据
